Billionaire Stanley Druckenmiller Just Bet Big on This Hot IPO Stock. Is It a Buy?

Legendary macro investor Stanley Druckenmiller, who generated >30% annual returns historically, was active in Q3 13-F filings with top buys including Insmed, an iShares MSCI Emerging Markets ETF and Amazon, and top sells Philip Morris, Entegris and Coherent; notably he acquired 4.26 million shares of newly public StubHub (unclear if via IPO or open market). StubHub’s debut has disappointed—shares plunged from a $23.50 IPO to under $11—despite Q3 results that beat revenue ($468.1m vs. $451.4m consensus), showed GMS +11% (or +24% ex-Taylor Swift) and adjusted EBITDA up 21% to $67.5m with margin expansion; however management withheld fourth-quarter guidance, prompting analyst price-target cuts. Regulatory risk is rising — the U.K. is reportedly considering a ban on above-face-value resales and the CMA is investigating pricing practices — and at a roughly $4bn market cap (~15x run-rate EBITDA) the stock will need clearer growth visibility to justify recovery, making Druckenmiller’s stake a high-conviction but risk-exposed position.

Analysis

Stanley Druckenmiller, a noted macro investor with a historic Duquesne track record averaging >30% annual returns and no losing years, filed notable Q3 13-F activity including buys in Insmed, an iShares MSCI Emerging Markets ETF and Amazon, and sells of Philip Morris, Entegris and Coherent; his most conspicuous move was acquiring 4.26 million shares of newly public StubHub (unclear if via IPO allocation or open-market). StubHub's IPO (listed Sept. 16 at $23.50) has underperformed, sliding to below $11 on Nov. 19, even as its first public-quarter results showed underlying strength: GMS rose 11% to $2.43bn (24% ex-Taylor Swift impact), revenue was $468.1m versus a $451.4m consensus, and adjusted EBITDA rose 21% to $67.5m with margins expanding to 14%. Market disappointment centered on management withholding fourth-quarter guidance, prompting analyst price-target cuts despite the beat; GAAP was distorted by IPO accounting. Political and regulatory risk in the U.K. is material—reports of a potential ban on resale above face value and a CMA probe into drip pricing and pressure-selling practices—while competition and U.S. consumer softness could further constrain growth, leaving StubHub valued at roughly $4bn or ~15x run-rate EBITDA and in need of clearer growth visibility to justify a recovery.

Key Decisions for Investors

• Defer initiating a meaningful new long position in STUB until management provides fourth-quarter guidance or the company outlines how it will navigate U.K. regulatory risks,
• Consider a small, tactical exposure sized to risk appetite given the ~15x run-rate EBITDA valuation, but hedge regulatory and event risk through options or correlated short positions,
• If already long, trim positions or tighten protective hedges given the stock's slide from a $23.50 IPO to under $11 and the unresolved CMA investigation,
• Monitor three near-term catalysts before increasing exposure: Q4 guidance from management, outcomes or clarifications on U.K. ticket-resale rules and the CMA probe, and subsequent analyst revisions to price targets